Date & Time of Session - 2/26/26 - from 12-1PM

Overview
Bispecific T-cell engager (BiTE) therapies are rapidly expanding in oncology, with more agents gaining FDA approval and transforming treatment options for various cancers. As these therapies become more prevalent, pharmacists across care areas including the emergency department, ICU, BMT, and general medicine are encountering patients receiving BiTEs more frequently. Despite this growing presence, there is limited system-wide education within UofL Health on BiTE therapy agents, mechanisms, and their unique toxicity profiles. This lecture will help pharmacists better understand approved and emerging BiTE therapies, recognize target-specific adverse effects, and identify early signs of serious complications such as CRS and ICANS. 

Objectives
Upon completion of this activity, the participant will be able to:
1. Explain the mechanism of action and pharmacologic characteristics of bispecific T-cell engager (BiTE) therapies. 
2. Review FDA-approved and emerging BiTE agents, including their target antigens and therapeutic roles. 
3. Identify key target-specific adverse effects associated with BiTE therapy.

Speakers
Jayme Sturgeon, PharmD
PGY1 Pharmacy Resident
UofL Health – Louisville, Kentucky

    Session date: 
    02/26/2026 - 12:00pm EST to 04/24/2026 - 11:59pm EDT
    Add to calendar: 
    • 1.00 ACPE

      In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

      This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers. Course JA-UAN Number: JA0000312-9999-25-067-L01-P

    Please login or register to take this course.
    Faculty List: 
    Speaker(s)

    Jayme Sturgeon, PharmD

    has no relevant financial relationships to disclose at this time.